美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

羅氏控股

41.09

-0.2400-0.58%

成交量：73.32萬

成交額：3,016.93萬

市值：2,660.18億

市盈率：26.49

高：41.34

開：41.32

低：41.01

收：41.33

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

羅氏(RHHBY)計劃未來五年在美國投資500億美元

羅氏製藥(RHHBY.US)羅可適®在華獲批用於治療復發型和原發進展型多發性硬化症

羅氏(RHHBY.US)口服PI3Kα抑制劑“伊那利塞”國內獲批上市

羅氏(RHHBY.US)突破性療法遞交監管申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RHHBY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"羅氏控股","latestPrice":41.09,"timestamp":1746546000000,"preClose":41.33,"halted":0,"volume":733221,"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"交易中","change":-0.24,"latestTime":"05-06 11:40:00 EDT 延時","open":41.32,"high":41.34,"low":41.0075,"amount":30169294.571250003,"amplitude":0.008045,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1746561600000},"marketStatusCode":2,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.33,"volumeRatio":0.865242},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":0.865242,"shares":6474029800,"dividePrice":1.469385,"high":41.34,"amplitude":0.008045,"preClose":41.33,"low":41.0075,"week52Low":30.03,"pbRate":"6.91","psRate":"3.52","week52High":44.31,"institutionHeld":0,"latestPrice":41.09,"eps":1.550894,"divideRate":0.03576,"volume":733221,"delay":15,"ttmEps":1.550894,"open":41.32,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.66,"twentyDayClose":36,"sixtyDayClose":39.77},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RHHBY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529634009","title":"羅氏(RHHBY)計劃未來五年在美國投資500億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529634009","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529634009?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 16:41","pubTimestamp":1745311271,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，罗氏控股(RHHBY)未来五年将在美国投资500亿美元用于制药和诊断业务，相关计划包括扩大和升级肯塔基州、印第安纳州、新泽西州、俄勒冈州和加利福尼亚州的制造和分销能力。罗氏还计划建立一家生产工厂，以支持下一代减肥药的扩产，但没有透露工厂的位置。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2523942971","title":"羅氏製藥(RHHBY.US)羅可適®在華獲批用於治療復發型和原發進展型多發性硬化症","url":"https://stock-news.laohu8.com/highlight/detail?id=2523942971","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523942971?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 21:19","pubTimestamp":1743427176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏制药今日宣布，其旗下创新药罗可适正式获得中国国家药品监督管理局批准，每六个月静脉输注一次给药，用于治疗成人复发型多发性硬化症和成人原发进展型多发性硬化症，中国多发性硬化症患者将有望获得全球先进的全新治疗选择。复发型多发性硬化症病程反复发作，最终可能导致永久性残疾;原发进展型多发性硬化症患者自发病开始，病情会持续进展恶化，患者运动、感觉和认知功能持续下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1271992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","BK4007","BK1191","03165","01477","BK1574"],"gpt_icon":0},{"id":"2519819196","title":"羅氏(RHHBY.US)口服PI3Kα抑制劑“伊那利塞”國內獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819196","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819196?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 10:49","pubTimestamp":1741920588,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月14日，罗氏(RHHBY.US)宣布， PI3Kα 抑制剂“伊那利塞”获批上市，与哌柏西利和氟维司群(内分泌疗法)联合用药治疗内分泌治疗耐药(包括在辅助内分泌治疗期间或之后出现复发)、 PIK3CA 突变、激素受体(HR)阳性、人表皮生长因子受体 2(HER2)阴性、局部晚期或转移性乳腺癌成人患者(受理号：JXHS2400037/8)。伊那利塞是一种创新口服靶向治疗药物，对 PI3Kα 的抑制有高效力和特异性，同时有独特的作用机制可降解 PI3Kα 突变体，能为 HR 阳性、PIK3CA 突变的乳腺癌患者提供良好的耐受性、持久的疾病控制并有可能改善预后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1261810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)口服PI3Kα抑制剂“伊那利塞”国内获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2517543461","title":"羅氏(RHHBY.US)突破性療法遞交監管申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543461","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517543461?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 20:48","pubTimestamp":1741265300,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏今天宣布，美国FDA已接受该公司为抗CD20抗体obinutuzumab递交的补充生物制品许可申请，用于治疗狼疮性肾炎。新闻稿指出，obinutuzumab是首个在狼疮性肾炎随机3期临床试验中显示出完全肾脏缓解益处的抗CD20单克隆抗体。在狼疮性肾炎中，致病B细胞驱动持续性炎症，从而损伤肾脏。通过使用obinutuzumab耗竭致病B细胞，可针对狼疮性肾炎的根本原因，以帮助更好地控制该疾病，保护肾脏免受进一步损伤，并可能预防或延缓疾病进展至终末期肾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)突破性疗法递交监管申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"盤前","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1746072000000}}}